LB Pharmaceuticals (LBRX) Q3 2026 earnings summary

Executive summary

• LB-102 is in Phase 3 NOVA-2 for schizophrenia and Phase 2 ILLUMINATE-1 for bipolar I depression; NOVA-3, a 52-week open-label safety and tolerability trial, continues enrolling.

• Phase 3 schizophrenia topline data are expected in 1H 2027; no product revenue was generated in Q3 or the first nine months of 2026.

Financial highlights

• Q3 R&D expense was $51.5M vs. $2.4M a year earlier; G&A was $11.0M vs. $2.8M, and operating loss was $62.5M vs. $5.2M.

• Nine-month R&D was $110.3M vs. $8.3M; G&A was $28.2M vs. $8.3M, primarily reflecting advancement of clinical trials and increased headcount and operating costs.

• Net loss was $59.1M in Q3 2026 vs. $3.6M in Q3 2025, and $129.7M for 9M 2026 vs. $13.7M for 9M 2025.

• No revenue was generated in the three or nine months ended September 30, 2026 or 2025.

• Nine-month operating cash use was $125.2M; cash, cash equivalents and short-term investments totaled $403.8M at September 30, 2026.

Outlook and guidance

• NOVA-2 topline results are expected in 1H 2027, with a pre-NDA meeting with FDA expected in 2H 2027.

• ILLUMINATE-1 topline data are expected in Q1 2028; the adjunctive MDD Phase 2 trial is planned to start in early 2027, with topline data expected in 1H 2029.

• An update on potential trial design for predominantly negative symptoms of schizophrenia is expected in Q1 2027 following FDA engagement; a trial could begin in H2 2027, subject to regulatory feedback and other factors.

• LB-102 long-acting injectable development is ongoing; R&D and G&A expenses are expected to rise as trials advance, manufacturing scales and capabilities are built.

• Current cash, cash equivalents and short-term investments are expected to fund anticipated operating and capital needs beyond Q2 2029, based on current plans and assumptions.